approved EB-1A RFE Issued
Scientist
Chemical Biology · China · 2025-07-05
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.
Framework Evaluation
3 of 3 criteria metScholarly Articles (Met)
The petitioner authored 11 peer-reviewed articles and one book chapter in elite chemistry and biology journals.
Judging (Met)
The petitioner completed at least 37 peer reviews for major scientific journals, demonstrating her standing in the field.
Original Contributions (Met)
Her development of selective chemical probes and inhibitors for inflammatory diseases, supported by high citation percentiles and expert letters, constitutes major original contributions.
Why This Petition Was Approved
The petitioner satisfied the EB-1A criteria through 11 peer-reviewed publications in top-tier journals like Nature Communications and 288 citations, placing her in the top 1% of her field. She also demonstrated a significant track record of 37 peer review assignments for journals such as Cells and Cancers. Her original contributions were further validated by her role in developing novel inhibitors for inflammatory diseases and receiving funding from the NIH and NSF.
Request for Evidence (RFE)
Successfully AddressedThe RFE requested further proof that the petitioner's work was of major significance to the field. The response highlighted her top 1% citation ranking, global use of her findings, and funding from prestigious organizations.
RFE Targets
Original ContributionsScholarly Articles
Evidence
Evidence Types
Peer Reviewed Publications
Citations
Grants
Judging Experience
Original Contributions
Reference Letters Independent
Evidence Submitted
- 11 peer-reviewed publications in journals including Nature Communications and Angewandte Chemie
- 1 book chapter
- 288 citations placing her in the top 1% of cited authors in chemistry
- 37 peer review assignments for journals such as Cells, Cancers, and Molecules
- Evidence that 6 articles ranked in the top 10% of most-cited papers for their year
- Citations from researchers across 22 countries
- Development of novel inhibitors for cancer and inflammatory disease models
Similar Cases
Scientist
Pharmaceuticals · China
WeGreened EB-1A approved
Massachusetts 21 days 2025-05-29
The petition was approved based on the satisfaction of at least three EB-1A criteria: authorship of scholarly articles, participation as a judge of the work of others, and original scientific contributions of major significance. Specific metrics included 8 peer-reviewed publications in elite journals like Nature Microbiology, 260 citations placing him in the top 1% of his field, and the completion of over 20 peer reviews for high-impact journals.
Research Scientist
Research and Development · China
WeGreened EB-1A approved
Illinois 6 days 2024-11-05
The petition was approved based on the documentation of 24 peer-reviewed journal articles and a high citation count of 596, placing the applicant in the top 3% of her field. Additionally, her participation in at least 10 journal reviews satisfied the judging criterion. The case was further strengthened by evidence of support from the Department of Energy (DOE) and expert testimony regarding her impact on pharmaceutical development.
Professor
Chemicals · Egypt
WeGreened EB-1A approved
Saudi Arabia 12 days 2025-03-11
The petitioner demonstrated extraordinary ability through 306 peer-reviewed publications and 4,287 citations, placing him in the top 1% of researchers in his field. He satisfied the EB-1A criteria for judging the work of others with over 350 reviews and original contributions of major significance in catalysis and cancer therapeutics. The case was further supported by high-impact journal rankings and expert testimony regarding the work's global influence.
Scientist
Pharmaceuticals · India
WeGreened EB-1A approved
Massachusetts 410 days 2025-10-06
The petition was approved based on the petitioner's authorship of 27 peer-reviewed articles and 17 abstracts, which garnered 485 citations from researchers in over 40 countries. His work ranked in the top 10% of most-cited publications in pharmacology for several years. Additionally, he completed over 60 peer reviews and received research grants from the NIH and the National Research Foundation of South Korea.
Frequently Asked Questions
A approved EB-1A (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.
Browse More Cases
Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-07-05.
Browse all casesAt a Glance
Outcome approved
Processing 445 days
RFE Issued
Criteria Met 3 / 3
Evidence Types 6
EB-1A Case Data
Scraped Case Data
Total Cases 883
Success Rate 52.8%
Sustained 466
Dismissed 300
Related Pages
Get Case Insights
Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.
Join Waitlist